Breaking News Instant updates and real-time market news.

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

, ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

11:26
10/23/19
10/23
11:26
10/23/19
11:26

MacroGenics price target lowered to $18 from $39 at H.C. Wainwright

H.C. Wainwright analyst Debjit Chattopadhyay said the second interim overall survival analysis for the Phase 3 SOPHIA study of margetuximab reported by MacroGenics (MGNX) was "largely in line" with his expectation and his model reflects margetuximab approval in the U.S., as a fourth-line option limited to patients with the beneficial alleles. Given that potential future competition from ZW25 and/or ZW49 from Zymeworks (ZYME) remains a likely headwind, Chattopadhyay lowered his price target on MacroGenics shares to $18 from $39, though he keeps a Buy rating on the stock.

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

  • 26

    Oct

  • 06

    Nov

MGNX MacroGenics
$9.87

-1.17 (-10.60%)

06/05/19
STFL
06/05/19
NO CHANGE
Target $29
STFL
Buy
MacroGenics price target lowered to $29 from $36 at Stifel
Stephen analyst Kevin Willey lowered his price target for MacroGenics to $29 from $36, saying he expects maturing overall survival data from Sophia to command "meaningful" regulatory and commercial importance given what is likely to remain perceived to be a progression free survival benefit of uncertain clinical relevance. Willey tells investors in a research note that he is now less optimistic directionally-supportive OS data will manifest over time in the intent-to-treat patient population and has "minimal" confidence the early numerical OS separation favoring margetuximab in CD16A-158F patients will prove durable. He maintains a Buy rating.
07/18/19
HCWC
07/18/19
NO CHANGE
Target $39
HCWC
Buy
H.C. Wainwright sees 'nothing sinister' with MacroGenics regaining drug rights
H.C. Wainwright analyst Debjit Chattopadhyay sees nothing "inherently sinister" with flotetuzumab after MacroGenics regained the full rights to the drug. After speaking with management, the analyst says that ex-partner Servier was not been particularly engaged during the development process and that to date, MacroGenics has been funding both the U.S. and European studies. Further, flotetuzumab's emerging clinical profile remains consistent with what was presented at ASH 2018, and an updated presentation on the fully enrolled dose expansion cohort is expected at ASH 2019, Chattopadhyay tells investors in a research note. He keeps a Buy rating on MacroGenics shares with a $39 price target.
10/23/19
WEDB
10/23/19
NO CHANGE
Target $14
WEDB
Outperform
MacroGenics price target lowered to $14 from $23 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for MacroGenics to $14 from $23 following a worse-than-expected readout of the second interim OS analysis, prompted at 270 events, from the pivotal Phase 3 SOPHIA trial evaluating margetuximab and chemo against trastuzumab and chemo in patients with 3/4L HER2+ metastatic breast cancer. The analyst believes that "perhaps the most concerning read from the update" is the deterioration of margetuximab's relative benefit over trastuzumab in the CD16A 158F allele population, which saw a relative OS benefit of 6.7 months at the first interim analysis drop to 4.3 months at the second, largely due to better-than-expected survival in the trastuzumab arm. Nierengarten has an Outperform rating on the shares.
10/23/19
LEER
10/23/19
NO CHANGE
Target $18
LEER
Outperform
MacroGenics price target lowered to $18 from $26 at SVB Leerink
SVB Leerink analyst Jonathan Chang lowered his price target for $18 from $26 after the company announced data from the second interim overall survival analysis of the Phase III SOPHIA study of margetuximab in HER2+ metastatic breast cancer. While the analyst does not have the complete picture based on the top-line data disclosed in the press release, he is conservatively lowering his estimates based on his concern that any improvement in the data may only be incremental and in the context of a highly competitive and evolving breast cancer landscape. Chang reiterates an Outperform rating on the shares.
ZYME Zymeworks
$30.25

-0.26 (-0.85%)

08/30/19
STFL
08/30/19
INITIATION
Target $45
STFL
Buy
Zymeworks initiated with a Buy at Stifel
Stifel analyst Stephen Willey started Zymeworks with a Buy rating and $45 price target. After successfully leveraging its core antibody engineering platform technologies to generate multiple strategic collaborations and develop two mostly wholly-owned clinical candidates, Zymeworks is now approaching a number of clinical inflection points and appears "poised for meaningful value creation," Willey tells investors in a research note. He believes W25/ZW49 are unique assets within an "increasingly-crowded" development landscape of next-generation HER2- targeting agents.
08/30/19
08/30/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Orchard Therapeutics (ORTX) initiated with an Outperform at Oppenheimer. 2. Zymeworks (ZYME) initiated with a Buy at Stifel. 3. Modine Manufacturing (MOD) initiated with a Neutral at DA Davidson. 4. AMTD International (HKIB) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
09/30/19
RAJA
09/30/19
UPGRADE
RAJA
Strong Buy
Zymeworks upgraded to Strong Buy from Outperform at Raymond James
09/30/19
RAJA
09/30/19
UPGRADE
Target $40
RAJA
Strong Buy
Zymeworks upgraded to Strong Buy at Raymond James, price target to $40
Raymond James analyst David Novak upgraded Zymeworks to Strong Buy from Outperform and raised his price target to $40 from $36 after the company announced updated data from its ongoing Phase I clinical trial evaluating ZW25 monotherapy in patients with HER2-expressing solid tumors in a poster discussion presentation at ESMO. In a research note to investors, Novak says the ESMO data demonstrates that Zymeworks was "born to run" and sees additional positive data readouts and multiple potential clinical catalysts in the coming months.

TODAY'S FREE FLY STORIES

CLDR

Cloudera

$9.39

0.46 (5.15%)

12:55
11/20/19
11/20
12:55
11/20/19
12:55
Options
Cloudera put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Dec

FCAU

Fiat Chrysler

$15.13

-0.46 (-2.95%)

, GM

General Motors

$35.52

-0.87 (-2.39%)

12:53
11/20/19
11/20
12:53
11/20/19
12:53
Periodicals
UAW comments to Bloomberg on GM lawsuit, says confident contracts not affected »

The United Auto Workers…

FCAU

Fiat Chrysler

$15.13

-0.46 (-2.95%)

GM

General Motors

$35.52

-0.87 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$198.35

-1 (-0.50%)

, TWTR

Twitter

$29.31

-0.14 (-0.48%)

12:48
11/20/19
11/20
12:48
11/20/19
12:48
On The Fly
#SocialStocks: F8 conference announced, BI says Tik Tok outperforms Instagram »

Welcome to…

FB

Facebook

$198.35

-1 (-0.50%)

TWTR

Twitter

$29.31

-0.14 (-0.48%)

EROS

Eros International

$2.28

0.03 (1.33%)

GOOG

Alphabet

$1,307.23

-7.48 (-0.57%)

GOOGL

Alphabet Class A

$1,305.97

-6.62 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 06

    Feb

TGT

Target

$124.35

13.49 (12.17%)

, LOW

Lowe's

$117.75

4.34 (3.83%)

12:45
11/20/19
11/20
12:45
11/20/19
12:45
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have slumped a bit…

TGT

Target

$124.35

13.49 (12.17%)

LOW

Lowe's

$117.75

4.34 (3.83%)

GM

General Motors

$35.58

-0.81 (-2.23%)

FCAU

Fiat Chrysler

$15.18

-0.405 (-2.60%)

KNSA

Kiniksa

$8.68

1.7 (24.36%)

I

Intelsat

$7.06

0.98 (16.12%)

URBN

Urban Outfitters

$24.75

-3.98 (-13.85%)

PDD

Pinduoduo

$31.76

-8.95 (-21.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 03

    Dec

  • 05

    Dec

  • 10

    Dec

CGC

Canopy Growth

$17.67

2.35 (15.34%)

12:45
11/20/19
11/20
12:45
11/20/19
12:45
Options
Canopy Growth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$8.73

0.28 (3.31%)

, SNSS

Sunesis

$0.41

0.0022 (0.54%)

12:42
11/20/19
11/20
12:42
11/20/19
12:42
Conference/Events
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call »

Biotech Analysts Kumar…

ARQL

ArQule

$8.73

0.28 (3.31%)

SNSS

Sunesis

$0.41

0.0022 (0.54%)

LLY

Eli Lilly

$114.70

-0.43 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 17

    Dec

  • 30

    Jan

FB

Facebook

$198.38

-0.97 (-0.49%)

12:39
11/20/19
11/20
12:39
11/20/19
12:39
Hot Stocks
Facebook shares updates for 'brand safety' tools to give advertisers control »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

ALNY

Alnylam

$105.23

7.24 (7.39%)

12:37
11/20/19
11/20
12:37
11/20/19
12:37
Hot Stocks
FDA approves Alnylam's Givlaari for acute hepatic porphyria »

The Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 04

    Feb

TDC

Teradata

$27.39

0.5 (1.86%)

12:37
11/20/19
11/20
12:37
11/20/19
12:37
Hot Stocks
Teradata says not for sale after filing drives speculation »

Don Bilson, the head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

, UTX

United Technologies

$147.58

-0.87 (-0.59%)

12:35
11/20/19
11/20
12:35
11/20/19
12:35
Hot Stocks
Pratt & Whitney GTF engines selected by GoAir to power 72 A320neo aircraft »

Pratt & Whitney, a…

EADSY

Airbus

$0.00

(0.00%)

UTX

United Technologies

$147.58

-0.87 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

TDC

Teradata

$27.51

0.62 (2.31%)

12:33
11/20/19
11/20
12:33
11/20/19
12:33
Hot Stocks
Teradata says 'unequivocally not exploring a sale' »

In a statement to The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,308.50

-6.21 (-0.47%)

, GOOGL

Alphabet Class A

$1,306.60

-5.99 (-0.46%)

12:27
11/20/19
11/20
12:27
11/20/19
12:27
On The Fly
Game On: An exclusive talk with The Game Kitchen's Enrique Colinet »

In this week's edition of…

GOOG

Alphabet

$1,308.50

-6.21 (-0.47%)

GOOGL

Alphabet Class A

$1,306.60

-5.99 (-0.46%)

MSFT

Microsoft

$150.10

0.26 (0.17%)

SNE

Sony

$61.60

-0.28 (-0.45%)

NTDOY

Nintendo

$0.00

(0.00%)

ATVI

Activision Blizzard

$54.07

0.79 (1.48%)

EA

Electronic Arts

$98.77

2.22 (2.30%)

TTWO

Take-Two

$123.84

0.24 (0.19%)

TCEHY

Tencent

$0.00

(0.00%)

UBSFY

Ubisoft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 04

    Dec

  • 09

    Dec

FCAU

Fiat Chrysler

$15.48

-0.105 (-0.67%)

, GM

General Motors

$35.66

-0.73 (-2.01%)

12:26
11/20/19
11/20
12:26
11/20/19
12:26
Hot Stocks
Fiat Chrysler falls after GM alleges UAW bribes in new lawsuit »

General Motors (GM) filed…

FCAU

Fiat Chrysler

$15.48

-0.105 (-0.67%)

GM

General Motors

$35.66

-0.73 (-2.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$13.74

-0.33 (-2.35%)

12:25
11/20/19
11/20
12:25
11/20/19
12:25
Options
Sunrun call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

VRTX

Vertex

$215.06

0.06 (0.03%)

12:24
11/20/19
11/20
12:24
11/20/19
12:24
Recommendations
Vertex analyst commentary  »

Piper Jaffray reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/19
11/20
12:17
11/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRRX

Durect

$1.88

0.015 (0.80%)

12:16
11/20/19
11/20
12:16
11/20/19
12:16
Recommendations
Durect analyst commentary  »

H.C. Wainwright sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/19
11/20
12:16
11/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTI

British American Tobacco

$38.59

1.355 (3.64%)

, MO

Altria Group

$48.62

1.675 (3.57%)

12:15
11/20/19
11/20
12:15
11/20/19
12:15
Periodicals
FDA shelves plan to require sharp cut in nicotine in cigarettes, Bloomberg says »

The Department of Health…

BTI

British American Tobacco

$38.59

1.355 (3.64%)

MO

Altria Group

$48.62

1.675 (3.57%)

PM

Philip Morris

$84.89

1.44 (1.73%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

GM

General Motors

$35.72

-0.67 (-1.84%)

, FCAU

Fiat Chrysler

$15.49

-0.095 (-0.61%)

12:14
11/20/19
11/20
12:14
11/20/19
12:14
Periodicals
GM sues Fiat Chrysler over UAW bribe claims, AP reports »

General Motors (GM) is…

GM

General Motors

$35.72

-0.67 (-1.84%)

FCAU

Fiat Chrysler

$15.49

-0.095 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARAV

Aravive

$11.82

5.13 (76.68%)

12:11
11/20/19
11/20
12:11
11/20/19
12:11
Recommendations
Aravive analyst commentary  »

Aravive price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LK

Luckin Coffee

$26.78

-0.49 (-1.80%)

12:05
11/20/19
11/20
12:05
11/20/19
12:05
Options
Luckin Coffee call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

FCX

Freeport McMoRan

$11.32

0.035 (0.31%)

11:55
11/20/19
11/20
11:55
11/20/19
11:55
Options
Freeport McMoRan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
11/20/19
11/20
11:55
11/20/19
11:55
Conference/Events
William Blair SaaS analyst to hold a luncheon meeting »

SaaS Analyst Pfau holds a…

NEWT

Newtek Business Services

$23.09

-0.06 (-0.26%)

11:54
11/20/19
11/20
11:54
11/20/19
11:54
Hot Stocks
Newtek Business Services acquires majority stake in POS on Cloud »

Newtek Business Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.